Inclusion on the list of medicines approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of this medicinal product is substantial.
Clinical Added Value
minor
CISNAF provides a level IV (minor) in improvement in actual benefit (IAB) compared to technetium scintigraphy in the detection of bone metastases in lung, prostate and breast cancers because of its superiority in diagnostic performance and in the reduction in adverse effects compared with the comparator.
Listen
